Following its Phase 1 investigation, the CMA has found that Theramex s proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
LONDON, October 10, 2023 Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals.